

To: [redacted] [redacted]@rivm.nl; [redacted] [redacted]@rivm.nl; [redacted] [redacted]@rivm.nl
From: [redacted] 5.1.2e
Sent: Wed 1/13/2021 10:01:30 AM
Subject: FW: Contact regarding B.1.1.7 Variant
Received: Wed 1/13/2021 10:01:31 AM

Ter info. Laat het graag aan jullie of we er iets mee willen?

From: [redacted] 5.1.2e) <[redacted] 5.1.2e @uu.nl>
Sent: maandag 4 januari 2021 22:10
To: [redacted] 5.1.2e) <[redacted] 5.1.2e @uu.nl>
Cc: [redacted] 5.1.2e) <[redacted] 5.1.2e @uu.nl>; [redacted] 5.1.2e) <[redacted] 5.1.2e @uu.nl>
Subject: Contact regarding B.1.1.7 Variant

Dear [redacted] 5.1.2e,

Hello, my name is [redacted] 5.1.2e and I work at the Pharmacology Department with [redacted] 5.1.2e and [redacted] 5.1.2e. I contact you, as you hold a position at RIVM too.

Our group has been working in the detection of different diseases and therefore we developed specific primers for SARS-CoV-2 and the results were 100% specific with detection accuracy as good as the ones suggested by GISAID. The information is in the following manuscript (accepted) :

<https://scientific-reports-under-consideration.nature.com/posts/classification-and-specific-primer-design-for-accurate-detection-of-sars-cov-2-using-deep-learning>

Right now, we developed a primer set for variant B.1.1.7 using the same methodology. We have already started communication with researchers from other countries, and we thought that RIVM will be interested in having a specific test for the variant as it has a higher transmission, as well as other concerning properties. You can find all the information below:

<https://www.biorxiv.org/content/10.1101/2020.12.29.424715v1>

Design of Specific Primer Set for Detection of B.1.1.7 SARS-CoV-2 Variant using Deep Learning | bioRxiv

The SARS-CoV-2 variant B.1.1.7 lineage, also known as clade GR from Global Initiative on Sharing All Influenza Data (GISAID), Nextstrain clade 20B, or Variant Under Investigation in December 2020 (VUI – 202012/01), appears to have an increased transmissability in comparison to other variants. Thus, to contain and study this variant of the SARS-CoV-2 virus, it is necessary to develop a ...

www.biorxiv.org

Looking forward to your answer,

[redacted] 5.1.2e

Ce message électronique et tous les fichiers attachés qu'il contient sont confidentiels et destinés exclusivement à l'usage de la personne à laquelle ils sont adressés. Si vous avez reçu ce message par erreur, merci de le retourner à son émetteur. Les idées et opinions présentées dans ce message sont celles de son auteur, et ne représentent pas nécessairement celles de DANONE ou d'une quelconque de ses filiales. La publication, l'usage, la distribution, l'impression ou la copie non autorisée de ce message et des attachements qu'il contient sont strictement interdits.

This e-mail and any files transmitted with it are confidential and intended solely for the use of the individual to whom it is addressed. If you have received this email in error please send it back to the person that sent it to you. Any views or opinions presented are solely those of its author and do not necessarily represent those of DANONE or any of its subsidiary companies. Unauthorized publication, use, dissemination, forwarding, printing or copying of this email and its associated attachments is strictly prohibited.